ArticleIntensive care medicine2026
Risk heterogeneity within hypoinflammatory acute respiratory failure: continuous probabilities identify high-risk patients masked by binary classification.
Article in Intensive care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeBinary inflammatory subphenotype classification (hyperinflammatory vs. hypoinflammatory) may guide trial enrollment in acute hypoxemic respiratory failure (AHRF), but assumes within-category homogeneity. We determined whether continuous probabilities reveal clinically meaningful heterogeneity.
methodsWe analyzed 575 critically ill adults with AHRF (Pittsburgh Acute Lung Injury Registry) and validated findings in 1134 patients from the EDEN trial, the COVID-19 cohorts, and the RoCI registry. Continuous subphenotype probabilities were calculated using a parsimonious biomarker model (IL-6, sTNFR-1, bicarbonate; probability threshold 0.5). The primary outcome was 90-day mortality.
resultsAmong 575 patients, 77 patients (13%) were hyperinflammatory and 498 (87%) hypoinflammatory. Hyperinflammatory patients demonstrated prognostic homogeneity (mortality overall 55%, p = 0.72, across tertiles). Hypoinflammatory patients exhibited marked heterogeneity: 90-day mortality increased from 19 to 31% to 40% across probability tertiles (P < 0.001). Restricted cubic spline modeling demonstrated a strong non-linear relationship between continuous probabilities and mortality, with the steepest risk increases occurring below the 0.5 threshold. Clinical severity scores and biomarkers of immune activation increased progressively across hypoinflammatory tertiles (all P < 0.001). Among 330 patients with longitudinal sampling, rising probability trajectories within hypoinflammatory groups predicted 50-100% mortality vs. 16-40% for stable or declining trajectories (all P < 0.001); hyperinflammatory patients had poor outcomes regardless of trajectory. External validation confirmed heterogeneity and preserved non-linear probability-mortality patterns across cohorts. Similar patterns were observed with the procalcitonin-based model.
conclusionsBinary classification obscures substantial prognostic heterogeneity within hypoinflammatory AHRF patients. Continuous probability-based stratification may identify additional trial-eligible high-risk patients and improve enrollment strategies for subphenotype-guided trials.
Indexed as
Identifiers
42043553What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.